Form 8-K

8-K — APTARGROUP, INC.

Accession: 0000896622-26-000187

Filed: 2026-10-29

Period: 2026-10-29

CIK: 0000896622

SIC: 3089 (PLASTICS PRODUCTS, NEC)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — atr-20261029.htm (Primary)

EX-99.1 (atr-20260930x8kexx991.htm)

GRAPHIC (imagea.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: atr-20261029.htm · Sequence: 1

atr-20261029

0000896622FALSE00008966222026-10-292026-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 29, 2026

Date of Report (Date of earliest event reported)

AptarGroup, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-11846 36-3853103

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014

(Address of principal executive offices)

Registrant’s telephone number, including area code: 815-477-0424.

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, $.01 par value ATR New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2026, AptarGroup, Inc. announced certain information related to its results of operations for the quarter ended September 30, 2026. The press release regarding this announcement is furnished as Exhibit 99.1 hereto.

The information in Item 2.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press release issued by AptarGroup, Inc. dated October 29, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AptarGroup, Inc.

Date: October 29, 2026

By: /s/ Vanessa Kanu

Vanessa Kanu

Executive Vice President and

Chief Financial Officer

EX-99.1

Filename: atr-20260930x8kexx991.htm · Sequence: 2

Document

Exhibit 99.1

Aptar Reports Third Quarter 2026 Results

Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results for the period ended September 30, 2026, as compared to the corresponding period of the last fiscal year.

Third Quarter 2026 Highlights

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)

•Reported sales increased 6% and core sales increased 5%

•Reported net income was $33 million and reported earnings per share were $0.51, impacted by deconsolidation of the Russian subsidiary

•Adjusted earnings per share were $1.52, at the higher end of the guidance range, compared to $1.62 in the prior year period at comparable exchange rates

•Adjusted EBITDA margin was 21.3%, compared to 23.2% in the prior year quarter

•Returned $61 million in the quarter and $272 million year-to-date to shareholders through share repurchases and dividends

•Subsequent to the quarter, the Board of Directors approved an increase in the quarterly cash dividend from $0.48 to $0.50

“We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range. Our Pharma pipeline remains strong, with continued focus on building the pipeline and converting opportunities into future growth. New technologies and development programs are expanding the role we can play with customers across the drug development cycle. Beauty and Closures also delivered strong top-line growth, including double-digit core sales growth in Closures, where innovation in beverage dispensing continues to gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully. These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.

Third Quarter Results

For the quarter ended September 30, 2026, reported sales increased 6% to $1.02 billion compared to $961 million in the prior year and core sales increased 5% compared to the prior year period.

Third Quarter Segment Sales Analysis

(Change Over Prior Year)

Pharma Beauty Closures Total AptarGroup

Reported Sales Growth 2% 9% 11% 6%

Currency Effects (1)

1% 0% (1)% 0%

Acquisitions / Deconsolidation (2)% (1)% 1% (1)%

Core Sales Growth 1% 8% 11% 5%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

Pharma’s reported sales increased 2% compared to the prior year period and core sales increased 1%. Adjusting for emergency medicine destocking, Pharma delivered 8% core sales growth in the quarter. Performance was supported by continued growth across a number of end markets, including central nervous system and pulmonary therapies, nasal decongestants, eye care and dermal drug delivery solutions, and demand related to biologics, vaccines and GLP-1 therapies. These growth drivers were partially offset by the anticipated reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin of 36.4% a decline of 80 basis points, remaining above our long-term target despite a short-term unfavorable product mix related to destocking. Royalties and productivity improvements continued to positively impact margins.

Beauty’s reported sales increased 9% when compared to the prior year period, with core sales growth of 8%. There was increased demand for prestige fragrance dispensing, color cosmetics, as well as hair care applications, and pass throughs of higher input costs also contributed positively. Adjusted EBITDA margin was 11.4%, a decline of 70 basis points, including unfavorable mix and ongoing challenges in North American operations.

Closures’ reported sales rose 11% from the prior year period, with core sales growth of 11%. Beverage and food sales grew significantly, led by strong demand for bottled water and concentrates, continued momentum from our latest beverage dispensing closure innovation, as well as strong condiment sales. Pass throughs of higher input costs contributed positively to core sales growth, however, the dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin to 15.5%.

During the third quarter, Aptar deconsolidated its Russian subsidiary following a governmental decree placing the subsidiary under external administration and the resulting loss of control. Aptar recorded a $58.0 million loss on deconsolidation which included approximately $30.0 million of cash held by the subsidiary. The combined impact was $61.2 million before tax, including approximately $2.6 million of related receivable reserves and $0.5 million of related legal costs; and $60.4 million after tax, or $0.94 per diluted share.

Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. The third quarter reported effective tax rate was 45.6%, reflecting the non-deductible tax impact of the deconsolidation of the Russian subsidiary. The adjusted effective tax rate was 23.4%, compared to the prior year period’s reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.

Nine Months Year-to-Date Results

For the nine months ended September 30, 2026, reported sales increased 8% to $3.03 billion compared to $2.81 billion in the prior year and core sales increased 2%.

Nine Months Year-To-Date Segment Sales Analysis

(Change Over Prior Year)

Pharma Beauty Closures Total AptarGroup

Total Reported Sales Growth 4% 12% 7% 8%

Currency Effects (1)

(3)% (4)% (3)% (4)%

Acquisitions / Deconsolidation (1)% (4)% 1% (2)%

Core Sales Growth 0% 4% 5% 2%

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

For the nine months ended September 30, 2026, Aptar’s reported earnings per share were $3.00, a decrease of 37%, which was also impacted by the deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ago. For the first nine months of 2026, adjusted earnings per share were $4.13 and decreased 10% from prior year adjusted earnings per share of $4.60, including comparable exchange rates. The current year had a reported effective tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the prior year reported and adjusted effective tax rates of 20.4% and 21.9%, respectively.

Outlook

Regarding Aptar’s outlook, Touya stated, “We expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and injectables and without the headwind from emergency medicine destocking. Our Pharma pipeline remains strong, with new technologies and development programs expanding our reach across therapeutic areas and advancing opportunities for future growth. Closures continues its great momentum, with innovation helping drive increased demand, particularly for our beverage technologies. In Beauty, we remain focused on improving our long-term North American trajectory, while we continue to see pockets of healthy demand in areas, such as prestige fragrance, globally.”

Aptar currently expects adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective tax rate range of 17.5% to 19.5%. The earnings per share guidance range is assuming a 1.12 Euro to USD exchange rate.

Cash Dividends and Share Repurchases

During the third quarter, Aptar repurchased approximately 234 thousand shares for $30 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.50 per share. The payment date is December 3, 2026, to stockholders of record as of November 12, 2026.

Open Conference Call

There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Core sales also exclude material acquisitions and, for the three and nine months ended September 30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Russia deconsolidation impacts comprise the loss on deconsolidation of our Russian subsidiary and related receivable reserves and legal costs described above, which we exclude because they resulted from a government action rather than from the operations of our businesses and therefore do not reflect the underlying performance of our remaining operations. For the three and nine months ended September 30, 2026 and 2025, “Other special items” include costs incurred related to non-ordinary-course litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products. These costs are excluded because they do not reflect our core operating performance. Please refer to “Legal Proceedings” within Note 13 - Commitments and Contingencies within Aptar’s Form 10-K for the year ended December 31, 2025 and subsequent SEC filings for more information. Adjusted EBITDA margin is adjusted EBITDA divided by reported net sales. Non-GAAP financial measures may not be comparable to similarly titled non-GAAP financial measures provided by other companies. Aptar’s management believes these non-GAAP financial measures provide useful information to our investors because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect Aptar’s core operating performance. These non-GAAP financial measures also provide investors with certain information used by Aptar’s management when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition-related costs and other special items.

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries and certain supply chain disruptions; as well as governmental actions affecting our foreign operations and assets, including the loss of control over, and our ability to recover value from, our Russian operations; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to keep pace with competition and technological advances, including in connection with the shifting of Pharma origination to less regulated markets; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate and cash flow; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key products or accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, interest rate volatility; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor Relations Contact:

Mary Skafidas

mary.skafidas@aptar.com

815-479-5530

Media Contact:

Katie Reardon

katie.reardon@aptar.com

815-479-5671

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(In Thousands, Except Per Share Data)

Consolidated Statements of Income

Three Months Ended

September 30,

Nine Months Ended

September 30,

2026

2025

2026

2025

Net Sales $ 1,019,119 $ 961,131 $ 3,028,495 $ 2,814,445

Cost of Sales (exclusive of depreciation and amortization shown below) 646,196 598,046 1,938,146 1,747,931

Selling, Research & Development and Administrative 160,164 148,760 485,501 455,176

Depreciation and Amortization 75,544 75,234 230,910 210,785

Restructuring Initiatives 2,208 2,168 4,713 5,789

Operating Income 135,007 136,923 369,225 394,764

Other Income (Expense):

Interest Expense (15,790) (13,532) (48,733) (35,733)

Interest Income 1,930 2,400 8,359 7,094

Net Investment (Loss) Gain (1,011) (161) (1,160) 845

Loss on Russia Deconsolidation (58,020) — (58,020) —

Equity in Results of Affiliates 1,106 1,747 3,224 6,142

Gain from Remeasurement of Equity Method Investment — 26,518 — 26,518

Miscellaneous Expense, net (2,889) 232 (3,744) 226

Income before Income Taxes 60,333 154,127 269,151 399,856

Provision for Income Taxes 27,511 26,295 75,552 81,629

Net Income $ 32,822 $ 127,832 $ 193,599 $ 318,227

Net (Income) Loss Attributable to Noncontrolling Interests (226) (47) (382) 76

Net Loss (Income) Attributable to Redeemable Noncontrolling Interests 6 142 (368) 142

Net Income Attributable to AptarGroup, Inc. $ 32,602 $ 127,927 $ 192,849 $ 318,445

Net Income Attributable to AptarGroup, Inc. per Common Share:

Basic $ 0.51 $ 1.95 $ 3.03 $ 4.83

Diluted $ 0.51 $ 1.92 $ 3.00 $ 4.75

Average Numbers of Shares Outstanding:

Basic 63,523 65,709 63,733 65,989

Diluted 64,147 66,630 64,373 67,043

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Balance Sheets

September 30, 2026 December 31, 2025

ASSETS

Cash and Equivalents $ 204,176 $ 402,424

Short-term Investments 8,121 7,109

Accounts and Notes Receivable, Net 883,939 803,830

Inventories 582,605 537,845

Prepaid and Other 157,950 142,354

Total Current Assets 1,836,791 1,893,562

Property, Plant and Equipment, Net 1,635,530 1,676,479

Goodwill 1,067,152 1,077,898

Other Assets 572,153 604,780

Total Assets $ 5,111,626 $ 5,252,719

LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY

Short-Term Obligations $ 350,681 $ 343,531

Accounts Payable, Accrued and Other Liabilities 872,133 822,913

Total Current Liabilities 1,222,814 1,166,444

Long-Term Obligations 1,024,735 1,139,433

Deferred Liabilities and Other 202,894 234,617

Total Liabilities 2,450,443 2,540,494

Redeemable Noncontrolling Interests 28,048 26,244

Total Mezzanine Equity 28,048 26,244

AptarGroup, Inc. Stockholders' Equity 2,614,324 2,668,096

Noncontrolling Interests in Subsidiaries 18,811 17,885

Total Stockholders' Equity 2,633,135 2,685,981

Total Liabilities, Mezzanine Equity and Stockholders' Equity $ 5,111,626 $ 5,252,719

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Statement of Cash Flows

Nine Months Ended September 30,

2026

2025

Cash Flows from Operating Activities:

Net income $ 193,599 $ 318,227

Adjustments to reconcile net income to net cash provided by operations:

Depreciation 198,044 177,412

Amortization 32,866 33,373

Stock-based compensation 33,043 36,772

Provision for CECL 4,374 516

Loss (gain) on disposition of fixed assets 484 77

Loss on Russia deconsolidation 58,020 —

Net loss (gain) on remeasurement of equity securities 1,160 (845)

Deferred income taxes (5,257) (31,851)

Defined benefit plan expense 6,898 10,232

Equity in results of affiliates (3,224) (6,142)

Gain on remeasurement of equity method investment — (26,518)

Impairment loss 5,007 —

Changes in balance sheet items, excluding effects from foreign currency adjustments:

Accounts and other receivables (101,728) (66,812)

Inventories (56,698) (22,782)

Prepaid and other current assets (17,906) (28,064)

Accounts payable, accrued and other liabilities 60,132 6,950

Income taxes payable (5,250) (1,281)

Retirement and deferred compensation plan liabilities (6,183) (5,891)

Retirement and deferred compensation plan assets 420 (7,314)

Other changes, net (8,023) 247

Net Cash Provided by Operations 389,778 386,306

Cash Flows from Investing Activities:

Capital expenditures (191,965) (183,600)

Proceeds from government grants — 3,308

Proceeds from sale of property, plant and equipment 1,544 2,103

(Purchases) and maturities of short-term investments (1,462) 2,813

Acquisition of business, net of cash acquired and release of escrow (156) (28,221)

Acquisition of intangible assets, net (1,933) (4,301)

Investment in equity securities — (7,258)

Cash balance of deconsolidated subsidiary (29,977) —

Notes receivable, net 1,355 37

Net Cash Used by Investing Activities (222,594) (215,119)

Cash Flows from Financing Activities:

Proceeds from notes payable and overdrafts 20,826 2,105

Repayments of notes payable and overdrafts (21,281) (1,946)

Proceeds of short term revolving credit facility, net 50,000 144,620

Proceeds from long-term obligations 6,112 1,204

Repayments of long-term obligations (160,897) (36,490)

Payment of contingent consideration obligation (3,730) —

Dividends paid (92,054) (89,287)

Proceeds from stock option exercises 22,420 14,869

Purchase of treasury stock (179,973) (190,005)

Redeemable noncontrolling interest 1,106 703

Net Cash Used by Financing Activities (357,471) (154,227)

Effect of Exchange Rate Changes on Cash (7,961) 16,253

Net Decrease in Cash and Equivalents and Restricted Cash (198,248) 33,213

Cash and Equivalents and Restricted Cash at Beginning of Period 404,849 223,844

Cash and Equivalents and Restricted Cash at End of Period $ 206,601 $ 257,057

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Three Months Ended

September 30, 2026

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 1,019,119 $ 453,970 $ 357,372 $ 207,777 $ — $ —

Reported net income $ 32,822

Reported income taxes 27,511

Reported income before income taxes 60,333 122,589 5,363 (22,985) (30,774) (13,860)

Adjustments:

Restructuring initiatives 2,208 406 1,827 (25) —

Net investment loss 1,011 — — — 1,011

Russia deconsolidation impact 61,161 3,137 9,555 40,626 7,843

Other special items 3,095 3,095 — — —

Adjusted earnings before income taxes 127,808 129,227 16,745 17,616 (21,920) (13,860)

Interest expense 15,790 15,790

Interest income (1,930) (1,930)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 141,668 129,227 16,745 17,616 (21,920) —

Depreciation and amortization 75,544 35,911 23,965 14,561 1,107

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 217,212 $ 165,138 $ 40,710 $ 32,177 $ (20,813) $ —

Reported net income margins (Reported net income / Reported Net Sales) 3.2 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 21.3 % 36.4 % 11.4 % 15.5 %

Three Months Ended

September 30, 2025

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 961,131 $ 445,410 $ 327,768 $ 187,953 $ — $ —

Reported net income $ 127,832

Reported income taxes 26,295

Reported income before income taxes 154,127 124,759 40,073 14,714 (14,287) (11,132)

Adjustments:

Restructuring initiatives 2,168 919 550 702 (3)

Net investment loss 161 — — — 161

Gain from remeasurement of equity method investment (26,518) — (26,518) — —

Transaction costs related to acquisitions 748 584 164 — —

Purchase accounting adjustments related to acquisitions and investments 1,148 — 1,148 — —

Other special items 4,400 4,400 — — —

Adjusted earnings before income taxes 136,234 130,662 15,417 15,416 (14,129) (11,132)

Interest expense 13,532 13,532

Interest income (2,400) (2,400)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 147,366 130,662 15,417 15,416 (14,129) —

Depreciation and amortization 75,234 35,107 24,332 14,921 874

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 222,600 $ 165,769 $ 39,749 $ 30,337 $ (13,255) $ —

Reported net income margins (Reported net income / Reported Net Sales) 13.3 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 23.2 % 37.2 % 12.1 % 16.1 %

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Nine Months Ended

September 30, 2026

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 3,028,495 $ 1,350,697 $ 1,088,461 $ 589,337 $ — $ —

Reported net income $ 193,599

Reported income taxes 75,552

Reported income before income taxes 269,151 339,843 38,396 1,434 (70,148) (40,374)

Adjustments:

Restructuring initiatives 4,713 345 4,545 311 (488)

Net investment loss 1,160 — — — 1,160

Realized gain on investments included in net investment loss above 88 — — — 88

Russia deconsolidation impact 61,161 3,137 9,555 40,626 7,843

Transaction costs related to acquisitions 83 83 — — —

Purchase accounting adjustments related to acquisitions and investments 145 145 — — —

Other special items 10,899 10,899 — — —

Adjusted earnings before income taxes 347,400 354,452 52,496 42,371 (61,545) (40,374)

Interest expense 48,733 48,733

Interest income (8,359) (8,359)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 387,774 354,452 52,496 42,371 (61,545) —

Depreciation and amortization 230,910 110,814 73,438 43,312 3,346

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 618,684 $ 465,266 $ 125,934 $ 85,683 $ (58,199) $ —

Reported net income margins (Reported net income / Reported Net Sales) 6.4 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 20.4 % 34.4 % 11.6 % 14.5 %

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)

Nine Months Ended

September 30, 2025

Consolidated Pharma Beauty Closures Corporate

& Other Net Interest

Net Sales $ 2,814,445 $ 1,297,466 $ 968,324 $ 548,655 $ — $ —

Reported net income $ 318,227

Reported income taxes 81,629

Reported income before income taxes 399,856 358,465 81,382 44,593 (55,945) (28,639)

Adjustments:

Restructuring initiatives 5,789 1,177 1,571 2,944 97

Net investment gain (845) — — — (845)

Gain from remeasurement of equity method investment (26,518) — (26,518) — —

Transaction costs related to acquisitions 1,092 584 508 — —

Purchase accounting adjustments related to acquisitions and investments 1,148 — 1,148 — —

Other special items 4,400 4,400 — — —

Adjusted earnings before income taxes 384,922 364,626 58,091 47,537 (56,693) (28,639)

Interest expense 35,733 35,733

Interest income (7,094) (7,094)

Adjusted earnings before net interest and taxes (Adjusted EBIT) 413,561 364,626 58,091 47,537 (56,693) —

Depreciation and amortization 210,785 100,424 65,869 41,943 2,549 —

Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) $ 624,346 $ 465,050 $ 123,960 $ 89,480 $ (54,144) $ —

Reported net income margins (Reported net income / Reported Net Sales) 11.3 %

Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) 22.2 % 35.8 % 12.8 % 16.3 %

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Income before Income Taxes $ 60,333 $ 154,127 $ 269,151 $ 399,856

Adjustments:

Restructuring initiatives 2,208 2,168 4,713 5,789

Net investment loss (gain) 1,011 161 1,160 (845)

Realized gain on investments included in net investment loss (gain) above — — 88 —

Russia deconsolidation impact 61,161 — 61,161 —

Gain from remeasurement of equity method investment — (26,518) — (26,518)

Transaction costs related to acquisitions — 748 83 1,092

Purchase accounting adjustments related to acquisitions and investments — 1,148 145 1,148

Other special items 3,095 4,400 10,899 4,400

Foreign currency effects (1) (371) 9,866

Adjusted Earnings before Income Taxes $ 127,808 $ 135,863 $ 347,400 $ 394,788

Provision for Income Taxes $ 27,511 $ 26,295 $ 75,552 $ 81,629

Adjustments:

Restructuring initiatives 557 561 1,240 1,488

Net investment loss (gain) 247 39 284 (207)

Realized gain on investments included in net investment loss (gain) above — — 22 —

Russia deconsolidation impact 785 — 785 —

Gain from remeasurement of equity method investment — — — —

Transaction costs related to acquisitions — 182 20 268

Purchase accounting adjustments related to acquisitions and investments — 172 49 172

Other special items 788 1,078 2,815 1,078

Foreign currency effects (1) (63) 2,014

Adjusted Provision for Income Taxes $ 29,888 $ 28,264 $ 80,767 $ 86,442

Net (Income) Loss Attributable to Noncontrolling Interests $ (226) $ (47) $ (382) $ 76

Net (Income) Loss Attributable to Redeemable Noncontrolling Interests $ 6 $ 142 $ (368) $ 142

Net Income Attributable to AptarGroup, Inc. $ 32,602 $ 127,927 $ 192,849 $ 318,445

Adjustments:

Restructuring initiatives 1,651 1,607 3,473 4,301

Net investment loss (gain) 764 122 876 (638)

Realized gain on investments included in net investment loss (gain) above — — 66 —

Russia deconsolidation 60,376 — 60,376 —

Gain from remeasurement of equity method investment — (26,518) — (26,518)

Transaction costs related to acquisitions — 566 63 824

Purchase accounting adjustments related to acquisitions and investments — 976 96 976

Other special items 2,307 3,322 8,084 3,322

Foreign currency effects (1) (308) 7,852

Adjusted Net Income Attributable to AptarGroup, Inc. $ 97,700 $ 107,694 $ 265,883 $ 308,564

Average Number of Diluted Shares Outstanding 64,147 66,630 64,373 67,043

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 0.51 $ 1.92 $ 3.00 $ 4.75

Adjustments:

Restructuring initiatives 0.02 0.02 0.05 0.06

Net investment loss (gain) 0.01 — 0.01 (0.01)

Realized gain on investments included in net investment loss (gain) above — — — —

Russia deconsolidation 0.94 — 0.94 —

Gain from remeasurement of equity method investment — (0.40) — (0.40)

Transaction costs related to acquisitions — 0.01 — 0.01

Purchase accounting adjustments related to acquisitions and investments — 0.02 — 0.02

Other special items 0.04 0.05 0.13 0.05

Foreign currency effects (1) — 0.12

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.52 $ 1.62 $ 4.13 $ 4.60

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.

AptarGroup, Inc.

Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)

(In Thousands)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Net Cash Provided by Operations $ 167,598 $ 177,606 $ 389,778 $ 386,306

Capital Expenditures (69,006) (63,313) (191,965) (183,600)

Proceeds from Government Grants — — — 3,308

Free Cash Flow $ 98,592 $ 114,293 $ 197,813 $ 206,014

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)

Three Months Ending

December 31,

Expected 2026

2025

Income before Income Taxes $ 91,522

Adjustments:

Restructuring initiatives 4,048

Curtailment gain related to restructuring initiatives (115)

Net investment loss 1,328

Transaction costs related to acquisitions 368

Purchase accounting adjustments related to acquisitions and investments 645

Other special items 3,960

Foreign currency effects (1) (2,485)

Adjusted Earnings before Income Taxes $ 99,271

Provision for Income Taxes $ 17,252

Adjustments:

Restructuring initiatives 1,015

Curtailment gain related to restructuring initiatives (30)

Net investment loss 325

Transaction costs related to acquisitions 125

Purchase accounting adjustments related to acquisitions and investments 110

Other special items 970

Foreign currency effects (1) (468)

Adjusted Provision for Income Taxes $ 19,299

Net Loss Attributable to Noncontrolling Interests $ 130

Net Income Attributable to Redeemable Noncontrolling Interests $ (56)

Net Income Attributable to AptarGroup, Inc. $ 74,344

Adjustments:

Restructuring initiatives 3,033

Curtailment gain related to restructuring initiatives (85)

Net investment loss 1,003

Transaction costs related to acquisitions 243

Purchase accounting adjustments related to acquisitions and investments 535

Other special items 2,990

Foreign currency effects (1) (2,017)

Adjusted Net Income Attributable to AptarGroup, Inc. $ 80,046

Average Number of Diluted Shares Outstanding 65,796

Three Months Ending

December 31,

Expected 2026

2025

Net Income Attributable to AptarGroup, Inc. Per Diluted Share $ 1.13

Adjustments:

Restructuring initiatives 0.05

Curtailment gain related to restructuring initiatives —

Net investment loss 0.01

Transaction costs related to acquisitions —

Purchase accounting adjustments related to acquisitions and investments 0.01

Other special items 0.05

Foreign currency effects (1) (0.03)

Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share (2) $1.39 - $1.47 $ 1.22

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.

(2) AptarGroup’s expected adjusted earnings per share range for the fourth quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per share and 19.4% on adjusted earnings per share.

GRAPHIC

Filename: imagea.jpg · Sequence: 6

Binary file (4819 bytes)

Download imagea.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Oct. 29, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Oct. 29, 2026

Entity Registrant Name

AptarGroup, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-11846

Entity Tax Identification Number

36-3853103

Entity Address, Address Line One

265 Exchange Drive

Entity Address, Address Line Two

Suite 301

Entity Address, City or Town

Crystal Lake

Entity Address, State or Province

Entity Address, Postal Zip Code

60014

City Area Code

815

Local Phone Number

477-0424

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $.01 par value

Trading Symbol

ATR

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Entity Central Index Key

0000896622

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration